Market Research Logo

Will Theranos Turn the Lab Industry Upside Down?

Will Theranos Turn the Lab Industry Upside Down?

In this report we explore the disruptive attributes that Theranos is claiming and discuss the likelihood that they have cracked the code on scaling microfluidics. We also explore the various distribution outlets Theranos is pursuing, with a particular emphasis on the Walgreens partnership - a partnership which, if successful, will drive disruptive change far beyond laboratory diagnostics, potentially redefining primary care, patient access, chronic-disease management, and population health.


Diagnostics: The Front Line of Care
The Starting Line: Has Theranos scaled microfluidic technology across a
comprehensive menu of tests?
Disruptive Attributes of Microfluidic platforms
A Review of the unique disruptive claims of Theranos' product offering
Scaling Microfluidics - So, Are we There Yet?
Scaling Microfluidics - Summary and Our Humble Opinion
Now What? - Looking At Potential Go-To-Market Strategy
Price - The Other Disruptive Attribute(s)
Distribution Strategies
What are Walgreens ambitions in the healthcare marketplace?
A Walgreens Solution - What makes for an effective Patient-Access Solution?
The Cruelest Irony of All?
Risks and Open Questions
So What Do We Think About Theranos?
Board of Directors
Theranos Test Menu
Theranos Patents
Known investors
Lab Industry: Facts and Figures
Phoenix Expansion
Typical Testing for Chronic Disease Management
Theranos Test Results
References

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report